These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 17138135)

  • 41. Biomarkers for prostate cancer.
    Makarov DV; Loeb S; Getzenberg RH; Partin AW
    Annu Rev Med; 2009; 60():139-51. PubMed ID: 18947298
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Proteomic analysis of bone cancer: a review of current and future developments.
    Bhattacharyya S; Byrum S; Siegel ER; Suva LJ
    Expert Rev Proteomics; 2007 Jun; 4(3):371-8. PubMed ID: 17552921
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients.
    Beneduce L; Prayer-Galetti T; Giustinian AM; Gallotta A; Betto G; Pagano F; Fassina G
    Cancer Detect Prev; 2007; 31(5):402-7. PubMed ID: 18035503
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prostate-specific antigen in clinical practice.
    Loeb S; Catalona WJ
    Cancer Lett; 2007 Apr; 249(1):30-9. PubMed ID: 17258389
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications.
    Shah RB; Chinnaiyan AM
    Adv Anat Pathol; 2009 May; 16(3):145-53. PubMed ID: 19395877
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis.
    Rostad K; Hellwinkel OJ; Haukaas SA; Halvorsen OJ; Øyan AM; Haese A; Budäus L; Albrecht H; Akslen LA; Schlomm T; Kalland KH
    APMIS; 2009 Aug; 117(8):575-82. PubMed ID: 19664128
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer.
    Gross M; Top I; Laux I; Katz J; Curran J; Tindell C; Agus D
    Clin Cancer Res; 2007 Apr; 13(7):1979-86. PubMed ID: 17404077
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Prostatic specific antigen: role and significance in urologic practice].
    Manolović D; Pejcić T; Milović N
    Srp Arh Celok Lek; 1994; 122(5-6):171-3. PubMed ID: 17977420
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of serum and urinary myeloid related protein-14 as a marker for early detection of prostate cancer.
    Müller H; Haug U; Rothenbacher D; Stegmaier C; Brenner H
    J Urol; 2008 Oct; 180(4):1309-12; discussion 1312-3. PubMed ID: 18707695
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
    Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
    Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry.
    Garbis SD; Tyritzis SI; Roumeliotis T; Zerefos P; Giannopoulou EG; Vlahou A; Kossida S; Diaz J; Vourekas S; Tamvakopoulos C; Pavlakis K; Sanoudou D; Constantinides CA
    J Proteome Res; 2008 Aug; 7(8):3146-58. PubMed ID: 18553995
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Proteome analysis of prostate cancer.
    Kuruma H; Egawa S; Oh-Ishi M; Kodera Y; Maeda T
    Prostate Cancer Prostatic Dis; 2005; 8(1):14-21. PubMed ID: 15477873
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Indications and timing for prostate biopsy, diagnosis of early stage prostate cancer and its definitive treatment: a clinical conundrum in the PSA era.
    Punnen S; Nam RK
    Surg Oncol; 2009 Sep; 18(3):192-9. PubMed ID: 19282170
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer.
    Byrne JC; Downes MR; O'Donoghue N; O'Keane C; O'Neill A; Fan Y; Fitzpatrick JM; Dunn M; Watson RW
    J Proteome Res; 2009 Feb; 8(2):942-57. PubMed ID: 19093873
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
    Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
    Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [New biomarkers for prostate cancer].
    Suzuki H; Shimbo M; Ichikawa T
    Nihon Rinsho; 2005 Feb; 63(2):351-9. PubMed ID: 15714991
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
    Lilja H; Ulmert D; Vickers AJ
    Nat Rev Cancer; 2008 Apr; 8(4):268-78. PubMed ID: 18337732
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Proteomic detection of prostate-specific antigen using a serum fractionation procedure: potential implication for new low-abundance cancer biomarkers detection.
    Solassol J; Marin P; Demettre E; Rouanet P; Bockaert J; Maudelonde T; Mangé A
    Anal Biochem; 2005 Mar; 338(1):26-31. PubMed ID: 15707932
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Meanings of prostate-specific antigen testing as narrated by men with localized prostate cancer after primary treatment.
    Hedestig O; Sandman PO; Widmark A; Rasmussen BH
    Scand J Urol Nephrol; 2008; 42(2):101-9. PubMed ID: 17907052
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?
    Crawford ED; Abrahamsson PA
    Eur Urol; 2008 Aug; 54(2):262-73. PubMed ID: 18556114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.